Fennec Pharmaceuticals (FENC) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Fennec Pharmaceuticals (FENC) do?
Fennec Pharmaceuticals Inc (FENC) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells an intravenous formulation of sodium thiosulfate to protect children from cisplatin chemotherapy side effects. It sells the only approved therapy specifically designed to prevent chemotherapy-induced hearing loss in pediatric. It is worth $474.86M on the market and sold $66.41M over the last year.
- Market cap
- $474.86M
- P/E ratio
- 805.4×
- Annual sales
- $66.41M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 18, 2026
Brands and businesses behind FENC
- Pedmark: An injectable drug prescribed to reduce hearing loss in pediatric chemotherapy patients, generating revenue from direct hospital sales.
- Pedmarqsi: The European brand of sodium thiosulfate sold to healthcare providers to protect pediatric oncology patients from ototoxicity.
FENC’s flags, in plain English
Each flag is a number from Fennec Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Stupid Cash
Can pay this year's bills 6.1 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 0% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Wide Gross Margin
Gross margin of 94.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Priced for Perfection
Priced at 805.4 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about FENC
How big is Fennec Pharmaceuticals?
Fennec Pharmaceuticals’ market cap is $474.86M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $66.41M: what customers paid the company over the last year, before any costs.
What is FENC’s P/E ratio?
FENC’s P/E ratio is 805.4×. Investors pay about 805.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with FENC?
The business relies entirely on a single drug for all of its revenue, leaving it exposed if prescribing rates drop. That is one risk on Fennec Pharmaceuticals’ card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Fennec Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. FENC’s filings on SEC.gov. The Margin Monkey is research, not advice.
